Evolus, Inc. (NASDAQ: EOLS) reported an insider sale by President and Chief Executive Officer David Moatazedi on March 20, 2026. Moatazedi disposed of 13,669 shares of the company's common stock for aggregate proceeds of about $64,929.
The transaction carried a weighted average sale price of $4.7501 per share, with the individual share prices recorded between $4.7498 and $4.775. After the sale, Moatazedi's direct ownership in Evolus stands at 604,700 shares.
The disposition was carried out under a pre-established Rule 10b5-1 trading plan and was executed to cover tax withholding obligations arising from the settlement of restricted stock units (RSUs). The company has indicated the sale was procedural in nature and tied specifically to those tax obligations.
Market performance context: Evolus' stock has declined roughly 30% year-to-date and is trading near its 52-week low of $4.09. Separately, InvestingPro analysis flags the stock as appearing undervalued at current levels and lists the company among its most undervalued names.
InvestingPro also highlights operational and analyst developments. The platform notes that Evolus is "quickly burning through cash" while two analysts have recently revised earnings estimates upward. For investors seeking more detailed coverage, a comprehensive Pro Research Report on EOLS is available through InvestingPro, part of a wider coverage set that spans 1,400-plus U.S. equities.
In corporate updates beyond the insider sale, Evolus released its fourth-quarter 2025 results, registering revenue of $90.3 million versus the $90.75 million that had been expected - a modest shortfall. The company also adjusted its board composition, reclassifying director Vikram Malik from a Class III director to a Class II director to preserve balance among board classes following the departure of Simone Blank. Company communications frame the reclassification as a step to stabilize governance structure.
These items - the CEO's Rule 10b5-1 sale to satisfy RSU-related tax obligations, the quarter's revenue narrowly under expectations, the board-class adjustment, and the mixed signals from cash-burn and analyst estimate revisions - together form the most recent publicly reported developments for Evolus.
For reference: The sale details, ownership post-transaction, recent stock performance, InvestingPro observations, the Q4 2025 revenue figure, and the board reclassification are reported as disclosed by the company and third-party analysis noted above.